Northern Trust Corp boosted its position in shares of Trevena Inc (NASDAQ:TRVN) by 15.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 572,662 shares of the biopharmaceutical company’s stock after acquiring an additional 77,934 shares during the period. Northern Trust Corp owned approximately 0.98% of Trevena worth $1,318,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Northpointe Capital LLC grew its stake in shares of Trevena by 5.0% in the 2nd quarter. Northpointe Capital LLC now owns 1,221,479 shares of the biopharmaceutical company’s stock valued at $2,809,000 after purchasing an additional 58,295 shares during the period. Nationwide Fund Advisors grew its stake in shares of Trevena by 92.1% in the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 23,557 shares during the period. Teachers Advisors LLC grew its stake in shares of Trevena by 26.4% in the 2nd quarter. Teachers Advisors LLC now owns 98,153 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 20,482 shares during the period. Bourgeon Capital Management LLC grew its stake in shares of Trevena by 56.8% in the 2nd quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 19,200 shares during the period. Finally, Alliancebernstein L.P. grew its stake in shares of Trevena by 51.9% in the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 18,900 shares during the period. Hedge funds and other institutional investors own 56.26% of the company’s stock.
TRVN has been the topic of several analyst reports. Zacks Investment Research lowered Trevena from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Needham & Company LLC lowered their price objective on Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Trevena in a research note on Wednesday, November 8th. Barclays lowered Trevena from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $15.00 to $2.50 in a research note on Monday, October 16th. Finally, Oppenheimer reiterated a “buy” rating and issued a $5.00 price objective on shares of Trevena in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. Trevena presently has an average rating of “Buy” and an average target price of $8.09.
Trevena (NASDAQ:TRVN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.06. During the same period last year, the company earned ($0.57) earnings per share. equities research analysts anticipate that Trevena Inc will post -1.25 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Northern Trust Corp Raises Position in Trevena Inc (TRVN)” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/12/06/northern-trust-corp-raises-position-in-trevena-inc-trvn.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.